Exploration of a novel HRD signature (HRDsig) as a biomarker of first line FOLFIRINOX benefit in metastatic pancreatic cancer This abstract was presented at the 2022 European Society for Medical Oncology Congress. View the full abstract on esmo.org. Comprehensive Genomic Profiling September 7, 2022